Current treatment strategies in malignant pleural mesothelioma  with a treatment algorithm by Sayan, Mutlay et al.
REVIEW ARTICLES
289www.journals.viamedica.pl
Address for correspondence: Mutlay Sayan, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA;  
e-mail: ms2641@cinj.rutgers.edu
DOI: 10.5603/ARM.2019.0051
Received: 27.05.2019
Copyright © 2019 PTChP
ISSN 2451–4934
Mutlay Sayan1, Mehmet Fuat Eren2, Apar Gupta1, Nisha Ohri1, Ayse Kotek3, Ibrahim Babalioglu4,  
Sedenay Oskeroglu Kaplan5, Ozge Duran5, Ozlem Derinalp Or6, Funda Cukurcayir7, Neslihan Kurtul8,  
Beyhan Ceylaner Bicakci9, Tugce Kutuk10, Sukran Senyurek11, Ali Turk11, Salma K Jabbour1, Banu Atalar12
1Rutgers	Cancer	Institute	of	New	Jersey,	New	Brunswick,	New	Jersey,	USA
2Radiation	Oncology	Clinic,	Marmara	University	Istanbul	Pendik	Education	and	Research	Hospital,	Istanbul,	Turkey
3Department	of	Radiation	Oncology,	Dr.	Ersin	Arslan	Education	and	Research	Hospital,	Gaziantep,	Turkey
4Department	of	Radiation	Oncology,	Konya	Education	and	Research	Hospital,	Konya,	Turkey
5Department	of	Radiation	Oncology,	Mehmet	Akif	Inan	Education	and	Research	Hospital,	Sanliurfa,	Turkey
6Department	of	Radiation	Oncology,	Adana	City	Education	and	Research	Hospital,	Adana,	Turkey
7Department	of	Radiation	Oncology,	Balikesir	Government	Hospital,	Balikesir,	Turkey
8Department	of	Radiation	Oncology,	Kahramanmaras	Sutcu	Imam	University,	Kahramanmaras,	Turkey
9Department	of	Radiation	Oncology,	Saglik	Bilimleri	University,	Kartal	Dr.	Lutfi	Kirdar	Education	and	Research	Hospital,	Istanbul,	Turkey
10Department	of	Radiation	Oncology,	Malatya	Education	and	Research	Hospital,	Malatya,	Turkey
11Department	of	Radiation	Oncology,	Kahramanmaras	Necip	Fazil	City	Hospital,	Kahramanmaras,	Turkey
12Department	of	Radiation	Oncology,	Mehmet	Ali	Aydınlar	Acıbadem	University,	School	of	Medicine,	Istanbul,	Turkey
Current treatment strategies in malignant pleural mesothelioma 
with a treatment algorithm
Abstract
Malignant	pleural	mesothelioma	(MPM)	is	a rare	disease	with	a poor	prognosis.	The	main	therapeutic	options	for	MPM	include	
surgery,	chemotherapy,	and	radiation	therapy	(RT).	Although	multimodality	therapy	has	been	reported	to	improve	survival,	not	
every	medically	operable	patient	is	able	to	undergo	all	recommended	therapy.	With	improvements	in	surgical	techniques	and	
systemic	therapies,	as	well	as	advancements	in	RT,	there	has	been	a potential	new	paradigm	in	the	management	of	this	disease.	
In	this	review,	we	discuss	the	current	literature	on	MPM	management	and	propose	a functional	treatment	algorithm.
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Introduction
Malignant pleural mesothelioma (MPM) 
is an aggressive malignancy arising from the 
mesothelial cells lining the pleura. Asbestos 
exposure is the primary risk factor for MPM, 
causing chronic inflammation and mesothelial 
cell transformation by interference with mitotic 
spindles, release of oxygen species, and attrac-
tion of macrophages [1]. The latency period for 
development of MPM lasts often 20−40 years 
from initial exposure to asbestos [2]. Although 
the main risk factor is asbestos, erionite exposure 
can also lead to MPM [3]. Erionite is a naturally 
occurring fibrous mineral found in volcanic rocks 
and in other hydrothermal environments, such 
as those occurring in the Cappadocian region 
of Turkey and other geological sites, including 
parts of northern Italy and the western United 
States [4–6]. While the mechanism of carcino-
genesis by erionite is similar to asbestos [7, 8], 
experimental studies indicate that erionite is up 
to 800 times more carcinogenic than asbestos 
[9–11]. More recently it has been reported that 
inherited heterozygous germline mutations of 
the deubiquitylase BRCA-associated protein 1 
(BAP1) cause a high incidence of mesothelioma 
in some families and that BAP1 mutations lower 
the threshold of asbestos required to cause meso-
thelioma in animal models [12]. 
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Although MPM is a rare malignancy (up to 
30 cases per million), the incidence has been in-
creasing in recent years likely due to the lag time 
in tumor development following asbestos exposure 
[13–16]. Diagnosis of MPM is often delayed as the 
disease presents with vague symptoms, including 
pleuritic chest pain, dyspnea, and/or weight loss. 
Depending on patient- and disease-related factors, 
treatment options may include surgery, chemothe-
rapy, and radiation therapy (RT) and should be 
determined through a multidisciplinary mana-
gement approach in experienced cancer centers. 
Despite advancements in treatment modalities, 
the prognosis of malignant mesothelioma remains 
poor with a median overall survival (OS) of 12– 
–22 months [13,17–19]. Given the constantly 
evolving treatment paradigm, we herein evaluate 
the published data on therapeutic options for MPM 
and propose a functional treatment algorithm. 
Surgical resection
Surgery is an important part of MPM manage-
ment and can be applied with curative or palliative 
intent. In general, there are two main approaches to 
surgery: pleurectomy/decortication (P/D) and extra-
pleural pneumonectomy (EPP). EPP is a complex 
procedure including en-bloc removal of the lung, 
parietal and visceral pleura, diaphragm, and peri-
cardium [18, 19]. During P/D, complete resection 
of macroscopic disease is obtained with removal 
of the entire pleura. If the diaphragm and/or peri-
cardium are affected, they are also removed, and 
the procedure is called extended-P/D [20]. A partial 
resection of parietal or visceral pleura without re-
moval of all gross tumor is a debulking operation 
and is termed partial pleurectomy (PP) [21]. 
The optimal resection technique for MPM is 
highly debated due to limited evidence regarding 
comparisons of surgical techniques. Historically, 
EPP was considered to be the only procedure to 
achieve a complete resection, and therefore, was 
recommended to all operable patients [19, 22, 23]. 
However, even with EPP, 70–100% of patients are 
found to have positive margins [24, 25], which 
has resulted in a shift towards extended-P/D as 
the preferred surgical approach. 
Although nonrandomized controlled trials 
comparing surgical treatment with extended-P/D or 
EPP exist, retrospective series favor extended-P/D 
(Table 1) [26–38]. A meta-analysis published by 
Cao et al. compared EPP (n = 632) to extended-P/D 
(n = 513) from seven relevant studies [39]. This 
study demonstrated significantly lower periopera-
tive mortality (2.9% vs 6.8%; p = 0.02) and mor-
bidity (27.9% vs 62.0%; p < 0.0001) for patients 
who underwent extended-P/D compared to EPP. 
Additionally, Luckraz et al. contrasted EPP with 
P/D in the multi-modality management setting 
and found that P/D combined with postoperati-
ve adjuvant therapy was associated with better 
survival despite a higher proportion of patients 
Table 1. Studies of different surgical techniques for malignant pleural mesothelioma
Authors [reference] Study design N Overall survival P
EPP P/D
Bovolato	et al.	[26] Retrospective 1365 20.9	mo 24.6	mo 0.596
Aziz	et al.	[27] Retrospective 302 13	mo 14	mo NS
Branscheid	et al.[28] Retrospective 301 284	days 315	days SS
Flores	et al.	[29] Retrospective 663 10	mo 13	mo 0.47
Kostron	et al.	[30] Retrospective 167 23	mo 32	mo 0.031
Lang-Lazdunski	et al.	[31] Prospective 86 12.8	mo 23	mo 0.004
Luckraz	et al.	[32] Retrospective 217 10.3	mo 10.1	mo 0.09
Miyazaki	et al.	[33] Retrospective 39 16.5	mo 22.5	mo 0.13
Okada	et al.	[34] Retrospective 87 13	mo 17	mo 0.922
Pass	et al.	[35] Retrospective 96 9.4	mo 14.5	mo 0.001
Rena	et al.	[36] Retrospective 77 20	mo 25	mo NS
Sharkey	et al.	[37] Retrospective 362 4.7	mo 12.5	mo 0.001
Verma	et al.	[98] Retrospective 1307 19	mo 16	mo 0.120
Kai	et al.	[38] Retrospective 44 17	mo 34	mo 0.019
EPP	—	extrapleural	pneumonectomy;	NS	—	not	statistically	significant;	mo	—	months;	P/D	—	pleurectomy/decortication;	SS	—	statistically	significant
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who either had advanced disease or were sur-
gically less fit (median 26 months, range 11–40 
months) [32]. Furthermore, EPP without adjuvant 
therapy was found to be an independent risk 
factor for decreased OS on multivariate analysis 
(hazard ratio [HR] = 9.2). In 2012, Rena et al. 
compared the long-term postoperative quality of 
life (QoL) in 70 patients with MPM treated with 
EPP or P/D [36]. While median OS was similar 
between surgical techniques (median 28 vs 32 
months; p = 0.098), they reported that patients 
who underwent EPP had a higher postoperative 
complication rate (62% vs 24%; p = 0.002), a wor-
se long-term QoL, and a shorter residual life time 
after recurrent disease (median 9 vs 14 months; 
p = 0.001) when compared to P/D. More recently, Ta-
ioli et al. conducted the largest meta-analysis using 
24 distinct data sets to compare EPP (n = 1,391) 
to P/D (n = 1,512) (40). There was no significant 
difference in OS between P/D and EPP at two 
years (23.8% vs 25%; p = 0.8); however, periope-
rative 30-day mortality was significantly higher 
after EPP than after P/D (4.5% vs 1.7%; p < 0.05), 
and EPP was associated with more postoperative 
complications than P/D (up to 68% vs 33%). 
The Mesothelioma and Radical Surgery 1 
(MARS 1) study was the first feasibility trial in 
which 50 patients with MPM were randomized 
to EPP and hemi-thoracic radiotherapy or no 
EPP, after induction chemotherapy [41]. Median 
OS was lower in the EPP group (14.4 months vs 
19.5 months) with a HR for death of 2.75 (95% 
confidence interval [CI] 1.21–6.26; p = 0.016). 
Furthermore, there was a trend towards worse 
QoL in the EPP arm. As this study did not show 
a  survival advantage or improved QoL, the 
authors cautioned against the use of EPP [42]. 
In summary, although level I evidence favo-
ring one surgical procedure is lacking, a number 
of retrospective studies and meta-analyses have 
demonstrated as follows: a) long-term survival 
after EPP is similar or lower than extended-P/D; 
b) higher perioperative mortality and postopera-
tive morbidity with EPP; and c) a lower postope-
rative QoL in patients treated with EPP. National 
Comprehensive Cancer Network (NCCN) guide-
lines on MPM suggest P/D may be safer than EPP 
but do not conclude which procedure is oncolo-
gically superior because of the lack of data from 
randomized controlled trials. 
Systemic therapy 
Chemotherapy plays an important role in the 
management of MPM and is recommended as part 
of a multimodality regimen in medically operable 
patients either before or after surgery (Table 2) 
[24, 41, 43–58]. Trimodality therapy includes che-
motherapy, surgery, and RT and has been reported 
to provide median OS of up to 20 to 29 months in 
those who are able to complete the entire course 
of treatment [52, 59]. Chemotherapy alone is also 
recommended for medically inoperable patients, 
for those who refuse surgery, or in the setting of 
progressive disease [26, 60–69].
Current first-line chemotherapy for MPM 
consists of a doublet regimen of pemetrexed and 
cisplatin. The evidence for this regimen comes 
from a large phase III trial by Vogelzang et al., in 
which 448 medically inoperable chemotherapy
-naïve patients with MPM were randomly assi-
gned to receive either cisplatin as monotherapy 
or a combination of cisplatin-pemetrexed [70]. 
Patients treated with cisplatin-pemetrexed had 
significantly longer median OS (12.1 months vs 
9.3 months; p = 0.020), progression-free survival 
(5.7 vs 3.9 months; p = 0.001), and higher treat-
ment response rates (41% vs 16%, p ≤ 0.001). In 
2016, Zalcman et al. randomized 448 medically 
inoperable chemotherapy-naïve MPM patients 
with no bleeding or thrombosis to cisplatin-peme-
trexed alone or bevacizumab-cisplatin-peme-
trexed followed by maintenance bevacizumab 
[71]. OS was significantly increased with addition 
of bevacizumab (18.8 months vs 16.1 months; 
p = 0.0167); however, 71% of patients receiving 
bevacizumab and 62% receiving cisplatin-peme-
trexed alone had grade 3−4 adverse events. Throm-
boembolic events (6% vs 1%) and serious hyperten-
sion (23% vs 0%) were more frequent in the subjects 
who received bevacizumab. Based on this trial, 
NCCN guidelines recommend this regimen for beva-
cizumab-eligible patients with unresectable MPM. 
Alternative first-line combination chemothe-
rapy options include pemetrexed-carboplatin and 
gemcitabine-cisplatin [72–77]. In a phase II study, 
Ceresoli et al. treated 102 chemotherapy-naïve 
MPM patients who were not eligible for curative 
surgery with pemetrexed and carboplatin [73]. 
Median time to progression was 6.5 months and 
median OS was 12.7 months. More recently, Ka-
tirtzoglou et al. treated 62 chemotherapy-naïve 
MPM patients with pemetrexed and carboplatin in 
a phase II study [72]. Median OS was 14 months 
(range, 11.8–16.2 months) and median time to pro-
gression was 7 months (range, 5.8–8.2 months). 
A  combination of gemcitabine and cisplatin 
was used in 39 MPM patients in a phase II stu-
dy with a  reported median OS of 20.7 months 
(10.7–30.8 months) [75]. Based on these studies, 
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Table 2. Studies of trimodality therapy for malignant pleural mesothelioma
Authors [reference] Study design N Treatment Overall survival
Rosenzweig	et al.	[43] Prospective 36 NA-chemo	+	P/D	+	RT	 1	yr	75%
2	yr	53%
Treasure	et al.	[41] Prospective 112 NA-chemo	+	EPP	+	RT 1	yr	52%
Bille	et al.	[44] Prospective 25 NA-chemo	+	EPP	+	RT 1	yr	75%
2	yr	53%
Stahel	et al.	[45] Prospective 151 NA-chemo	+	EPP	+	RT 1	yr	70%
2	yr	23%
Hasegawa	et al.	[46] Prospective 42 NA-chemo	+	EPP	+	RT 2	yr	50%
Van	Schil	et al.	[47] Prospective 59 NA-chemo	+	EPP	+	RT 1	yr	70.2%
Federico	et al.	[48] Prospective 54 NA-chemo	+	EPP	+	RT 1	yr	59.2%
de	Perrot	et al.	[49] Retrospective 60 NA-chemo	+	EPP	+	RT 5	yr	10%
Rimner	et al.	[50] Prospective 45 NA-chemo	+	P/D	+	RT 1	yr	80%
2	yr	59%
Minatel	et al.	[51] Prospective 69 P/D	+	A-chemo	+	RT 1	yr	90%
2	yr	65%
Krug	et al.	[52] Prospective 77 NA-chemo	+	EPP	+	RT 1	yr	90%
2	yr	61.2%
Bolukbas	et al.	[53] Prospective 102 P/D	+	A-chemo	+	RT 1	yr	69%
2	yr	50%
Buduhan	et al.	[54] Retrospective 46 NA-chemo	+	EPP	+	RT Median	25	mo
Fahrner	et al.	[55] Retrospective 41 NA-chemo	+	EPP	+	RT 1	yr	71%
2	yr	28%
Hasani	et al.	[24] Retrospective 36 EPP	+	A-chemo	+	RT 1	yr	76%
Kimura	et al.	[56] Prospective 15 NA-chemo	+	EPP	+	RT 1	yr	43.1%
Thieke	et al.	[57] Prospective 62 NA-chemo	+	EPP	+	RT 1	yr	63%
2	yr	42%
Trousse	et al.	[58] Prospective 83 NA-chemo	+	EPP	+	RT 1	yr	62.4%
2	yr	32.2%
A-chemo	—	adjuvant	chemotherapy;	EPP	—	extrapleural	pneumonectomy;	NA-chemo	—	neo-adjuvant	chemotherapy;	mo	—	months;	P/D	—	pleurectomy/decorti-
cation;	RT	—	radiation	therapy;	yr	—	year
pemetrexed-carboplatin and gemcitabine-cispla-
tin are now considered to be acceptable first-line 
options. 
Subsequent systemic therapy options for 
MPM may include immune checkpoint inhi-
bitors such as pembrolizumab or nivolumab 
with (or without) ipilimumab [78–83]. In 2019, 
Scherpereel et al. reported the result of the IFCT-
1501 MAPS2 trial in which 125 MPM patients 
pre-treated with one or two lines of chemothe-
rapy were randomized to a combination of ipi-
limumab plus nivolumab or nivolumab alone 
[78]. One-year survival estimates were 49.2% 
[36.9–61.6] in the nivolumab group and 58.1% 
(45.8–70.3) in the nivolumab plus ipilimumab 
group. Nine (14%) patients in the nivolumab 
group and 16 (26%) in the combination group had 
grade 3–4 toxicities. A recently published phase 
II trial (INITIATE) also assessed the combination 
of ipilimumab and nivolumab in MPM patients 
who had progressed after at least one line of 
chemotherapy [79]. This study found that 68% 
of persons had disease control at 12 weeks, 29% 
had a partial response, and 38% had stable dise-
ase. The KEYNOTE-028 trial assessed the use of 
pembrolizumab as subsequent therapy in PD-L1 
positive MPM patients and recently reported that 
the median OS was 18 months with 20% grade 
3–4 toxicity [80]. These latest studies indicate 
that immunotherapy represents one of the most 
recent advances in management of MPM. 
Radiation therapy 
In patients with MPM, RT has been used 
as part of multimodality therapy with curative 
intent (Table 2) or administered alone as pallia-
tive therapy for pain relief [84, 85]. The RT dose 
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should be based on the purpose of treatment as 
delivery of RT to the entire hemithorax, which is 
challenging given the complex shape of the pleura 
and the proximity of critical organs such as the 
lungs and heart [86].
RT is commonly delivered after surgical 
intervention with or without chemotherapy and 
has been shown to decrease the local recurrence 
rate following EPP [87–90]. In a phase II study, 
Rusch et al. have assessed the feasibility of he-
mithoracic radiation (54 Gy) in 88 patients after 
surgical resection (70% underwent EPP) [87]. Pa-
tients with stage I–II disease had a median OS of 
22.8 months and those with stage III–IV disease 
had a median OS of 10 months. Only two patients 
treated with EPP had a local recurrence and five 
individuals had locoregional and distant recur-
rence. Krug et al. prospectively treated 77 subjects 
with neoadjuvant pemetrexed plus cisplatin, 
EPP, and adjuvant hemithoracic RT (54 Gy) [52]. 
Forty patients (52%) were able to complete all 
therapies with a median OS of 29.1 months. In 
the JMIG 0601 trial, Hasegawa et al. enrolled 
42 MPM patients to neoadjuvant pemetrexed plus 
cisplatin, EPP, and adjuvant hemithoracic RT 
(54 Gy) [46]. Significantly longer OS was ob-
served for patients who received trimodality 
therapy (40%) in comparison with patients who 
completed EPP but not RT (39.4 vs 11.4 months; 
p = 0.0243). As has been previously reported in 
multiple prospective studies, RT improves local 
control (LC) and OS as part of trimodality therapy 
with EPP; however, only about 50% of the patients 
are able to undergo all therapy. 
High-dose RT to the entire hemithorax was 
traditionally not recommended in patients with an 
intact lung as it was found to not improve survival 
and was associated with significant toxicity [91–
93]. With the recent trend in surgical management 
towards lung-sparing surgical techniques (P/D 
or extended-P/D), a new method using intensity 
modulated RT (IMRT) has been reported in the 
IMPRINT trial to adequately treat the peripheral 
pleural space that carries the highest risk of local 
recurrence while sparing critical structures [50]. 
In this phase II trial, Rimner et al. enrolled 45 
MPM patients to a trimodality regimen consisting 
of induction chemotherapy, P/D, and adjuvant 
hemithoracic RT using IMRT (50.4 Gy) [50]. When 
possible, the total mean lung dose was limited to 
21 Gy, ipsilateral lung V20Gy to ≤ 37% to 40%, and 
contralateral lung V20Gy to ≤ 7%. Twenty-seven 
patients (60%) were able to start radiation therapy. 
The one- and two-year OS rates for patients with 
resectable disease were 80% and 59%, respectively. 
Grade 2–3 radiation pneumonitis was reported in 
30%. Based on this trial, the NCCN guidelines cu-
rrently recommend consideration of hemithoracic 
IMRT following induction chemotherapy and P/D 
in centers with expertise. 
Diagnosis of MPM is often made by pleu-
ral biopsy via CT-guided needle biopsy, tho-
racoscopy, video-assisted thoracic surgery, or 
thoracotomy, which can all lead to tumor cell 
seeding and chest wall metastasis. Prophylactic 
RT is often used to prevent instrument-tract re-
currence; however, this has been controversial 
as older randomized trials demonstrated con-
flicting results [94–96]. A recent phase III trial 
(SMART) randomized 203 MPM patients with 
a  chest wall intervention to prophylactic RT 
(21 Gy in 3 fractions) or deferred RT [97]. No 
significant difference in procedure-tract recu-
rrence was observed between the groups (9% 
vs 16%; p = 0.14). Based on the SMART trial, 
routine prophylactic RT to prevent instrument
-tract recurrence after pleural intervention is no 
longer recommended. 
Conclusions
MPM is a rare disease with a poor prognosis 
but improvements in surgical techniques and 
systemic therapies as well as advancements 
in RT have led to a potential new paradigm in 
MPM management. Surgery for MPM is indi-
cated mainly as a part of trimodality therapy. 
Whether EPP or extended-P/D is the superior 
approach remains a highly debated topic, with 
a  shift towards extended-P/D in recent years. 
Chemotherapy plays an important role and is 
recommended as part of multimodality therapy as 
well as alone in locally advanced or progressive 
disease. The current first-line regimen consists of 
a combination of pemetrexed and cisplatin with 
alternatives, including pemetrexed-carboplatin 
and gemcitabine-cisplatin. Recent advancements 
in immunotherapy suggest the potential use of 
pembrolizumab or nivolumab with (or without) 
ipilimumab as subsequent systemic therapy. Al-
though the use of RT was historically limited to 
palliation, recent advances in treatment planning 
and delivery techniques allow RT to improve 
LC and OS as a part of trimodality therapy. We 
critically reviewed the literature and devised an 
evidence-based treatment algorithm for patients 
with MPM (Figure 1). Nevertheless, the best tre-
atment approach for MPM is determined through 
a  multidisciplinary approach in experienced 
cancer centers.
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A-chemo — adjuvant chemotherapy; chemo — chemotherapy; NA-chemo — neo-adjuvant chemotherapy; mo — months; RT — radiation therapy
Malignant pleural 
mesothelioma
Stage IIIB–IV or 
medically inoperable
Chemo or RT or best 
supportive care
[67–69, 84, 85] 
(level II–III evidence)
Median survival 4.8–11.3 mo
Stage I–IIIA
NA-chemo + surgery 
+ RT [41, 43–50, 52, 
54, 55, 56–58] 
(level II evidence)
1-year survival 43–90%
Surgery + A-chemo 
+ RT [24, 52, 53] 
(level II evidence)
1-year survival 69–90%
Progression
Chemo [63–66] 
(level I–III evidence)
Median survival 4.9–9.6 mo
Figure 1.	Treatment	algorithm	for	malignant	pleural	mesothelioma
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